Mitokinin, Inc.

Daniel De Roulet

Robert Joseph Devita

The present disclosure is directed, in part, to substituted purines, or pharmaceutically acceptable salts thereof, represented by formula (VIII): for the treatment and/or prevention of neurodegenerative disease, mitochondrial disease, fibrosis, and/or cardiomyopathy.

Substituted purines for the treatment of neurodegenerative and mitochondrial diseases

The disclosure is directed to compounds and pharmaceutically acceptable salts thereof for the treatment and/or prevention of neurodegenerative and/or mitochondrial diseases, such as Parkinson's disease and Leigh's disease. The compounds and pharmaceutically acceptable salts thereof are of the class of nitrogenous bases, for example, pyrimidines, purines, pteridines, and pharmaceutically acceptable salts thereof.

Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease

The disclosure is directed to compounds and pharmaceutically acceptable salts thereof for the treatment and/or prevention of neurodegenerative and/or mitochondrial diseases, such as Parkinson's disease and Leigh's disease. The compounds and pharmaceutically acceptable salts thereof are of the class of nitrogenous bases, for example, pyrimidines, purines, pteridines and pharmaceutically acceptable salts thereof.

Growing community of inventors

Old Westbury, NY, United States of America

Daniel De Roulet